Effects of triiodothyronine treatments on body and organ growth and the development of immune function in dwarf chickens.
The effects of triiodothyronine (T3) treatments on general body growth, long bone growth, primary lymphoid organ development, antibody production, and serum growth hormone (GH) and thyroid hormone levels were examined in two dwarf strains (sex-linked dwarf--SLD, and autosomal dwarf--ADW) and in a normal-growing control strain (K) of White Leghorn chickens. One-day-old male chicks from each of these strains were assigned to either an untreated control group or to one of the groups receiving a T3 supplement ranging from 0.01 to 1.0 ppm. General body growth and long bone growth were significantly (P less than 0.05) stimulated only within the SLD strain by the intermediate T3 dosages. The 1.0-ppm T3 dosage level resulted in depressed body weights within both the K and ADW strains but produced no significant changes within the SLD strain. Thymic growth was significantly stimulated due to treatments of 0.1 ppm T3 in the SLD strain (P less than 0.05) and 1.0 ppm T3 in both the SLD and ADW strains (P less than 0.001 and P less than 0.05, respectively). Bursal growth was significantly depressed (P less than 0.05) at all T3 dosage levels within the SLD strain while 0.01 and 0.1-ppm T3 treatments resulted in significant bursal growth stimulation in the K and ADW strains, respectively. Concomitant with the depressed bursal growth, antibody production was significantly depressed (P less than 0.05) within the SLD strain at the 1.0-ppm T3 dosage level. Antibody production was not significantly affected by any of the T3 treatments within the control K or ADW strains. Serum T3 levels were significantly increased in all strains by the T3 supplementation but thyroxine (T4) serum levels were affected only within the SLD strain. The 0.01-ppm T3 treatment resulted in a significant increase (P less than 0.05) in serum T4 levels within this strain and treatment group. The only increase (P less than 0.05) in GH levels due to T3 treatments occurred within the same SLD treatment group. The higher T3 treatments resulted in serum GH levels being severely depressed (P less than 0.01) in all strains.
D000818:Animals; D000917:Antibody Formation; D001835:Body Weight / Q000187:drug effects; D002645:Chickens / Q000254:growth & development; D004392:Dwarfism / Q000503:physiopathology / Q000662:veterinary*; D004912:Erythrocytes / Q000276:immunology; D005260:Female; D007109:Immunity / Q000187:drug effects*; D008099:Liver / Q000187:drug effects / Q000254:growth & development; D008297:Male; D024510:Muscle Development; D009132:Muscles / Q000187:drug effects; D009929:Organ Size / Q000187:drug effects; D011201:Poultry Diseases / Q000235:genetics; D014284:Triiodothyronine / Q000494:pharmacology*
D014284:Triiodothyronine